Nanosonics Limited (ASX: NAN) - Share Price
Current share price for NAN : $3.300 0.12 (3.77%)+
Nanosonics (NAN), an ASX-listed company, is involved in Manufacturing and distribution of the trophon ultrasound probe disinfector and its associated consumables and accessories and research, development and commercialization of infection control and decontamination products and related technologies.
NAN General Information +
| ASX Code | NAN |
| Website | N/A |
| Industry/Sector | Health Care Supplies |
| Market Cap ($M) | 986 |
| NAN Share Price | $3.300 |
| Day High | $3.320 |
| Day Low | $3.105 |
| Last Close | $3.180 |
| NAN Share Price Movement | $0.12 ( 3.77% ) |
Prices as at 16:41, 9 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Nanosonics Limited (NAN) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Nanosonics Limited (NAN) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Nanosonics Limited (NAN) price-sensitive announcements
NAN - Nanosonics to commence $20 million share buy-back program
Nanosonics Limited, a leader in infection prevention, announced on 5 November 2025 its int
Nanosonics Limited (NAN)
5 Nov 2025 | 9:34 AM
5 Nov 2025 | 9:34 AM
NAN - Appendix 4E
This document is the Appendix 4E for Nanosonics Limited, outlining its preliminary final r
Nanosonics Limited (NAN)
26 Aug 2025 | 8:27 AM
26 Aug 2025 | 8:27 AM
NAN - US FDA clearance received for next generation trophon
On 30 October 2020, Nanosonics Limited announced that it has received US FDA clearance for
Nanosonics Limited (NAN)
6 Aug 2025 | 9:29 AM
6 Aug 2025 | 9:29 AM
NAN - Nanosonics launches trophon3 and trophon2 Plus software
Nanosonics Limited announced the launch of two new products: the trophon3 and updated trop
Nanosonics Limited (NAN)
7 Jul 2025 | 8:25 AM
7 Jul 2025 | 8:25 AM
Nanosonics Limited (NAN) Recent ASX Announcements
NAN Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026F | $27.28 | $8.81 | 102.00% | 38.25 | 0.00 | 0.00% | 0.0% |
| 2025F | $13.51 | $4.36 | 8.40% | 77.29 | 0.00 | 0.00% | 0.0% |
| 2024A | $12.43 | $4.02 | -32.20% | 92.24 | 0.00 | 0.00% | 0.0% |
NAN Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 F | 2026 F | 2024 A | 2025 F | 2026 F | 2024 A | 2025 F | 2026 F | ||
| Ansell Limited (ANN) | $3,880M | 0.2270 | -0.1174 | 0.1576 | 14.4044 | 16.3202 | 14.0986 | 2.78% | 2.63% | 3.04% |
| Nanosonics Limited (NAN) | $926M | 0.5929 | -0.1883 | 0.3094 | 46.3378 | 57.0902 | 43.6006 | 0.00% | 0.00% | 0.00% |
| Polynovo Limited (PNV) | $739M | 1.5200 | -0.2011 | 0.9735 | 56.6138 | 70.8609 | 35.9060 | 0.00% | 0.00% | 0.00% |
NAN Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Michael Kavanagh | Chief Executive Officer, Managing Director | 30 Jul 2012 |
| Dr Larry Marshall | Non-Executive Director | 3 Oct 2023 |
| Ms Marie Elizabeth McDonald | Non-Executive Director | 24 Oct 2016 |
| Dr Tracey Leigh Batten | Non-Executive Director | 26 Sep 2023 |
| Mr Gerard Dalbosco | Non-Executive Director | 14 Jan 2025 |
| Ms Sarah Butler | Non-Executive Director | 19 Jan 2026 |
| Mr Steven Andrew Sargent | Non-Executive Director, Non-Executive Chairman | 6 Jul 2016 |
Nanosonics Limited (NAN) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 26 Feb 2026 | BUTLER, Sarah | Buy | Indirect Shares | 15,000 | $3.399 | $50,977.600 |
| 17 Sep 2025 | DALBOSCO, Gerard | Buy | Indirect Shares | 12,558 | $4.080 | $51,231.580 |
| 1 May 2025 | KAVANAGH, Michael | Sell | Direct Shares | 50,000 | $4.650 | $232,489.440 |
See all changes in directors' interest & trades for Nanosonics Limited (NAN) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
NAN Management
| Name | Position |
|---|---|
| Jason Burriss | Chief Financial Officer |
| Sunny Pillai | Chief Information Officer |
| Kimberly Hill | Chief Marketing Officer |
| Jonathan Burdach | Chief Medical Affairs and Scientific Officer |
| Rod Lopez | Chief Operating Officer and Regional President for Asia Pacific |
| Jodi Sampson | Chief People & Culture Officer |
| Derek Minihane | Chief Technology Officer |
| Matthew Carbines | General Counsel and Company Secretary |
| Matthew Carbines | General Counsel,Company Secretary |
| Ronan Wright | Regional President for Europe, UK and Middle East |
| Ken Shaw | Regional President for the United States, Canada and Latin America |
NAN Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Nanosonics Limited (NAN). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 24,241,974 (8%) | Selector Funds Management Limited |
| 18,913,333 (6.20%) | Maurie Stang |
| 17,086,290 (5.60%) | Pinnacle Investment Management Group Limited |
| 16,353,493 (5.40%) | Bernard stang |
| 16,022,967 (5.30%) | UBS Group AG and its related bodies corporate |
| 16,009,579 (5.30%) | Yarra Funds Management Limited |
NAN Calendar of Events
| Date | Event |
|---|---|
| 23 February 2027 | Report (Interim) |
| 25 August 2026 | Report (Annual) |
| 25 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
